A forum for researchers, students and applicants in the field of cyclodextrin technology
Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced
Niemann-Pick type C1 (NPC1) disease is a fatal neurovisceral disease for which there are no FDA approved treatments, though cyclodextrin
The annual National Niemann Pick Disease Family Conference will be held on August 15-18, 2019, in Bloomington, US. The conference
The first paper in the special issue of Nanomaterials “Nanoconstructs Based on Cyclodextrins” has been published. Mono-lactosyl β-CD (mono-Lac-β-CD) diminished
The team of Gerhard Wenz (Saarland University, Germany) has published a novel polyrotaxane: hydroxypropyl-β-cyclodextrin(HPBCD):poly(decamethylenephosphate) which has several advantages over HPBCD
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
CTD Holdings, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need,
The CDNews blog was created in July and after a short period of trial it started in September. During this
According to clinicaltrials.gov, currently, there are 14 cyclodextrin-related clinical trials that in the status of i) Not yet recruiting, ii)
Mallinckrodt Pharmaceuticals recently revealed findings of their completed registration trial for VTS-270 (Hydroxypropyl Betadex- HPBCD), a development product to treat
